ClinicalTrials.gg
Active, not recruitingNCT05032976Updated Apr 23, 2026

Korea Comirnaty Post-marketing Surveillance

An observational study in COVID-19, Vaccines and Adverse Effects, sponsored by Pfizer. Active, not recruiting at 1 site in South Korea. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Pfizer · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12,000
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Planned enrollment
10th of 28
12,000 · median 2,038
Started
2022
with 17 others
Observational
28 of 69
1 open now
Registered
14th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 10th largest by planned enrollment of the 28 observational ones that give a count, is one of 18 that started in 2022, is one of 28 observational ones, and was the 14th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

This study will collect information on the safety of BNT162b2 products for subjects who have been administered in a routine clinical practice from 05Mar2021 to 04Mar2027 in Korea, and will be conducted in accordance with the New Drug Re-Examination Guideline of the Ministry of Food and Drug Safety (MFDS).

Read the detailed description

This is an open-label, non-comparative, non-interventional, prospective, and multi-center study conducted in Korean health care centers by accredited physicians (investigator). The study population is Korean subjects who are scheduled for COVID-19 vaccination. BNT162b2 products will be administered according to the "Dosage and Administration" of the approved labeling. There is no visit or activity mandated by this study. The investigator will collect data from the subject's medical records and patient (subject) report outcome (PRO), and record the information on each subject's case report form (CRF).

Pfizer Pharmaceuticals Korea will conclude a post-marketing surveillance agreement with an investigator site before performing the study. Investigators at the institution that sign the agreement should prepare the CRFs from all the subjects who this vaccine was administered to after the start date of the study.

Each investigator will sequentially enroll all subjects to whom BNT162b2 products is prescribed for the first time according to the local product document and who agree to participate in this study by signing the data privacy statement used in place of the informed consent form until the total requested cases per center are collected for this study.

An electronic diary will be used in this study to collect adverse events that occur after injection. Follow-up exams will be carried out from after the first injection to before the second injection, and from after the second injection to 28 days after the second injection. Those who received booster doses will be followed up for the 28 days from the date of the booster dose. For the follow-up adverse event CRF, either an application using the mobile phones of subjects or entry on a paper questionnaire may be selected. The CRF will be filled out every day after the first and second injections. If an application is used, it is automatically sent as an eCRF. If a paper questionnaire is used, the questionnaire filled out after the first injection is collected at the time of the visit for the second injection, and the questionnaires filled out after the second injection and booster dose are collected 28 days after the second injection and 28 days after the booster dose respectively by mail.

To promote the collection of adverse events after injection, a reminder may be given by phone about entering the information and the collection of the CRF to subjects who gave consent beforehand. If it is difficult to record CRF due to the subject, the occurrence of adverse events can be confirmed by phone.

Safety is the primary interest of this study, which will be assessed based on adverse events (AEs) that occur during 28 days from the date of the first, second and booster doses of BNT162b2.

03

Conditions studied

  • COVID-19
  • Vaccines
  • Adverse Effects
  • SARS-CoV-2
  • Safety

Browse trials for

Keywords

  • COVID-19
  • Vaccines,
  • Adverse Effects
  • SARS-CoV-2
  • Safety
04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

the subjects who received the BNT162b2 under an approved label for use in Korea in contracted study sites.

Eligibility criteria

1. Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Korean subjects who are eligible for administration of BNT162b2 products (Including bivalent COVID-19 Vaccines for omicron) according to the locally approved and authorized label (indication, age criteria etc.)
  2. Evidence of a personally signed and dated data privacy statement indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study - Data privacy statement signed by the subjects and parents or legal representative for subjects aged under 19

2. Exclusion criteria Subjects meeting any of the following criteria will be excluded in the study

  1. Subjects who involved in the of use indicated in the locally approved and authorized label
  2. Subjects with a history of to any ingredients of this product or this product
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tozinameran (BNT162b2)

    Subjects aged 6 months and older who are scheduled for Tozinameran vaccination

    Biological: Tozinameran 12 Years of age and older · Biological: Tozinameran 5 to 11 Years of age · Biological: Tozinameran 6 months to 4 years of age

  • Riltozinameran (BNT162b2 OMI BA.1)

    Subject aged 12 years and older who are scheduled for Riltozinameran vaccination

    Biological: Riltozinameran 12 Years of age and older

  • Famtozinameran (BNT162b2 OMI BA.4-5)

    Subject aged 5 years and older who are scheduled for Famtozinameran vaccination

    Biological: Famtozinameran 12 Years of age and older · Biological: Famtozinameran 5 to 11 Years of age

  • Raxtozinameran (BNT162b2 OMI XBB.1.5)

    Subject aged 6 months to 4 years and 12 years and older who are scheduled for Raxtozinameran vaccination

    Biological: Raxtozinameran 12 years of age and older · Biological: Raxtozinameran 6 months to 4 years of age

Interventions

  • BiologicalTozinameran 12 Years of age and older

    BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.

  • BiologicalTozinameran 5 to 11 Years of age

    BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM. But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age.

  • BiologicalTozinameran 6 months to 4 years of age

    BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later. Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course. The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established. BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age.

  • BiologicalRiltozinameran 12 Years of age and older

    The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine. The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.

  • BiologicalFamtozinameran 12 Years of age and older

    The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine. The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.

  • BiologicalFamtozinameran 5 to 11 Years of age

    The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine. The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19.

  • BiologicalRaxtozinameran 12 years of age and older

    BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status. For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

  • BiologicalRaxtozinameran 6 months to 4 years of age

    BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.

06

What researchers measure

Primary outcomes

  1. Number of subjects with Solicited adverse events

    Solicited adverse events within 1 week (Day 1-7) after each dose of BNT162b2 products, and a number of subjects with such events will be collected.

    Time frame: 1 week after administration of BNT162b2 products

  2. Number of subjects with Unsolicited adverse events

    Unsolicited adverse events within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

Secondary outcomes

  1. Number of subjects with Adverse Events (AEs)

    All adverse events within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  2. Number of subjects with Serious Adverse Events

    All Serious adverse events within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  3. Number of subjects with Expected Adverse Events

    All expected adverse events within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  4. Number of subjects with Adverse Drug Reactions

    All adverse Drug Reactions within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  5. Number of subjects with Serious Adverse Drug Reactions

    All serious adverse drug reactions within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  6. Number of subjects with Expected Adverse Drug Reactions

    All expected adverse drug reactions within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

  7. Number of subjects with Unexpected Adverse Drug Reactions

    All unexpected adverse drug reactions within 28 days by its last dose, and a number of subjects with such events will be collected

    Time frame: 28 days after administration of BNT162b2 products

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2027, 58 months after the start.

Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 58 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 2, 2021
StartActual
Mar 18, 2022
Primary completionEst.
Jan 24, 2027
CompletionEst.
Jan 24, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05032976
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Mar 18, 2022
Primary completion
Jan 24, 2027 (estimated)
Completion
Jan 24, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion